1 / 19

Postoperative Radiotherapy after Mastectomy Trial - Chest Wall RT in Breast Cancer

This phase III randomized trial examines the selective use of postoperative radiotherapy after mastectomy in intermediate-risk breast cancer patients. It outlines eligibility guidelines, consent procedures, and reporting of serious adverse events.

sayler
Download Presentation

Postoperative Radiotherapy after Mastectomy Trial - Chest Wall RT in Breast Cancer

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. MRC SUPREMO(BIG 2-04)Selective Use of Postoperative Radiotherapy aftEr MastectOmy Phase III randomised trial of chest wall RT in intermediate- risk breast cancerKunkler I, Canney P, Price A, Anderson N, Dixon J, Sainsbury R, Aird E, Thomas G,Bowman A, Thomas J, Bartlett J, Devine I, Denvir M, McDonagh T, Russell N, Cairns J, Boon Chua, Karlsson P, Northridge D, van Tienhoven G, Velikova G,Walker A, Macdonald E

  2. Protocol V29 • Eligibility Guide – Non Neo-adjuvant & Neo-adjuvant • Informed Consent Procedures • SAE Guidelines • Supremo Team • Recruitment Agenda

  3. Protocol V29 • Implemented on the 14th February 2011 • 108 out of 157 sites confirmed approval for V29 • UK: 104 out of 117 • International: 4 out of 9 (5 China sites will continue to work to V27) • EORTC: 0 out of 31. New protocol approved in April 2011 and is due to be implemented by Summer 2011.

  4. Patient Consent Procedures 1 Patient Information • Patients should have a verbal explanation of the trial and be given most recent MREC-approved Patient Information Sheet (PIS) for the main SUPREMO trial/TRANS-SUPREMO and Quality of Life/Health Economics sub-studies (version 29)

  5. Patient Consent Procedures 2 Consent Form Completion • Consent forms must be printed on hospital headed paper & accompanied by centre’s standard radiotherapy information sheets • All participating patients must sign the most recent version of consent forms (separate consent forms for Main trial/TRANS-SUPREMO, Quality of Life/Health Economics substudies). • Patients must initial, not tick boxes • PI to countersign forms, but PI can delegate responsibility as appropriate (must be clearly documented in delegation log). • No trial procedures can be performed prior to the patient giving informed consent.

  6. Patient Consent Procedures 3 Consent Form Copies • 4 copies of signed consent forms required • Original copy should be kept in site folder • Copy given to patient • Copy sent to ISD CCTT • Copy kept in patient hospital notes

  7. Serious Adverse Events 1 SAE Definition • A SAE is defined as an untoward occurrence that: • Results in death • Is life threatening • Requires hospitalisation or prolongation of existing hospitalisation • Results in persistent disability or incapacity • Is a congenital anomaly/birth defect • Is otherwise considered medically significant by the investigator

  8. Serious Adverse Events 2 Expected Radiotherapy SAEs • For SUPREMO patients receiving radiotherapy the potential expected adverse events/reactions include: • Skin reactions leading to chest wall tenderness and itching • Chest wall pain • Pneumonitis (inflammation of the lung) causing shortness of breath • Osteitis (inflammation of the ribs) causing the ribs to fracture • Late cardiac damage • If any of the above expected reactions fall under the definition of SAE they should be listed on SAE/SUSARs form

  9. Serious Adverse Events 3 Chemotherapy SAEs

  10. Serious Adverse Events 4 Reporting • At the centre: • Use SAE/SUSAR form to report all SAEs (even if the SAE is chemotherapy related) • Fax copy to ISD Trials Unit within 24 hours (from site staff becoming aware) • Do not delay because of missing information and/or signatures • Local PI to assess whether unexpected, severity and/or related to radiotherapy • Provide missing information (and outcome information) as soon as it is known

  11. Serious Adverse Events 5 Processing • ISD Trials Unit will: • Allocate an SAE number • Forward initial report to CI immediately if local PI assesses event as unexpected • Advise the PI if SAE is evaluated as a SUSAR • Comply with NRES guidelines on reporting of SAEs • Report all SAEs to DMEC/MREC on an annual basis

  12. SUPREMO TeamEve Macdonald (eve.macdonald@nhs.net) Senior Trial CoordinatorJulian Lipscombe (jlipscombe@nhs.net) Trial CoordinatorLeigh Fell (leigh.fell@nhs.net) Trial CoordinatorAnn Moncrieff (ann.moncrieff@nhs.net) Data Manager ISD Cancer Clinical Trials Team Edinburgh nss.isdsupremo@nhs.net

  13. Trial Co-ordination Provided by ISD Trials Unit • Randomisation service • Advice on protocol and eligibility • Investigator Site Files (ISFs) • Regular newsflashes & website reports (www.supremo-trial.com) • 10% Source data monitoring

  14. Recruitment to date (as of 30/5/11) • Main trial 1078 • TRANS SUPREMO 850 • Quality of Life 611 • Cardiac substudy 53 • Health Economics 41

  15. Recruitment to date (cont.)

  16. Thank you for your time. Questions?

  17. ISD CANCER CLINICAL TRIALS TEAM

More Related